Contract development and manufacturing organisation and an injectables firm, Gland Pharma Ltd , on Monday (November 3) reported a 12.3% year-on-year increase in consolidated net profit (PAT) to ₹184 crore for the quarter ended September 30, 2025, up from ₹164 crore in Q2 FY25.

Consolidated revenue for the quarter grew 5.8% YoY to ₹1,486.8 crore from ₹1,405.8 crore. EBITDA rose 5.8% YoY to ₹314 crore, compared with ₹297 crore in the same quarter last year, while the EBITDA margin remained stable at 21.1%.

On a half-year basis, consolidated revenue increased 7%, and half-yearly EBITDA rose 21%, with the EBITDA margin at 23%. Quarterly adjusted EBITDA increased 13% YoY, with margins expanding 150 bps, while half-yearly adjusted EBITDA grew 26%, with margin improvement of 370 bps. Quarterl

See Full Page